Several other research analysts have also recently weighed in on the stock. StockNews.com began coverage on shares of Delcath Systems in a report on Monday. They set a sell rating on the stock. HC Wainwright lowered their price objective on shares of Delcath Systems from $25.00 to $19.00 and set a buy rating on the stock in a research report on Wednesday, August 10th. Finally, BTIG Research lowered their price objective on shares of Delcath Systems to $19.00 in a research report on Tuesday, November 15th.
Delcath Systems Stock Down 1.4 %
Shares of NASDAQ DCTH opened at $2.92 on Monday. The stock has a market capitalization of $25.11 million, a P/E ratio of -0.77 and a beta of 0.92. The company has a 50-day moving average price of $3.03 and a 200-day moving average price of $3.82. Delcath Systems has a 1 year low of $2.34 and a 1 year high of $10.24. The company has a debt-to-equity ratio of 2.55, a current ratio of 1.28 and a quick ratio of 1.15.
Institutional Trading of Delcath Systems
Several hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC bought a new stake in shares of Delcath Systems in the second quarter valued at approximately $40,000. Vanguard Group Inc. raised its position in shares of Delcath Systems by 5.7% in the first quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock valued at $2,309,000 after purchasing an additional 19,605 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of Delcath Systems in the first quarter valued at approximately $75,000. Cibc World Market Inc. raised its position in shares of Delcath Systems by 4.0% in the first quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after purchasing an additional 3,432 shares during the period. Finally, CI Investments Inc. bought a new stake in shares of Delcath Systems in the first quarter valued at approximately $559,000. Institutional investors own 26.18% of the company’s stock.
Delcath Systems Company Profile
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Get a free copy of the StockNews.com research report on Delcath Systems (DCTH)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.